Hip Stem Cell Injections: Can They Help Joint Pain and Mobility?

Chronic hip pain that flares with everyday movement, or with every mile for a runner, is one of the most common reasons adults in their 40s, 50s, and beyond start looking into options beyond physical therapy and anti-inflammatories. For some, that search leads to stem cell injections for hips, a regenerative approach explored before considering hip replacement surgery. This article covers what causes hip osteoarthritis, how the injections are thought to work, what the hip-specific evidence shows, current safety and regulatory status, how the approach compares with other treatments, and what the data suggests for runners. It is worth saying upfront: this remains an emerging area of research, not an approved or guaranteed solution.

What Causes Chronic Hip Pain and Osteoarthritis?

Hip osteoarthritis develops when the cartilage cushioning the ball-and-socket joint gradually breaks down, allowing bone surfaces to move with less protection between them. Over time this can lead to joint inflammation, stiffness, and pain that worsens with weight-bearing activity, with aging, prior injury, labral tears, biomechanical alignment, and cumulative joint stress as common contributing factors.

Conservative treatments such as NSAIDs, physical therapy, and corticosteroid injections are usually the starting point for managing symptoms and can meaningfully help many people, but they primarily manage symptoms rather than reverse the underlying degeneration. That gap is part of why regenerative options have drawn growing interest from patients without lasting relief from conservative care alone.

How Do Hip Stem Cell Injections Work?

Stem cell therapy here generally refers to mesenchymal stem cells (MSCs) collected from a patient's own bone marrow or adipose (fat) tissue and injected directly into the hip joint under image guidance. Researchers have proposed that these cells act mainly by suppressing pro-inflammatory activity within the joint while supporting regenerative signaling, rather than by physically regrowing new cartilage, with favorable, low-complication patterns reported in early-stage (Tönnis grade 1) hips, though authors framed these as preliminary (Mosconi et al., Frontiers in Surgery, 2026).

The general procedure involves harvesting cells, a bone marrow aspiration from the pelvis or a small liposuction-style collection of fat tissue, processing them, and injecting the resulting product into the hip joint under ultrasound or fluoroscopic guidance. This harvest-process-inject sequence is broadly consistent across the studies reviewed here, though exact protocols and cell sources vary between research groups.

What Does the Evidence Show for Stem Cell Injections for Hips?

A Smaller, Earlier-Stage Evidence Base Than the Knee

Unlike knee osteoarthritis, no Cochrane review or large randomized controlled trial exists specifically evaluating stem cell injections for hip osteoarthritis as of this writing. Researchers describe the hip literature as considerably more limited in scale and less standardized than the knee-OA evidence base, consisting mainly of small cohort studies, case series, and scoping or narrative reviews (Entessari & Oliveira, Regenerative Medicine, 2023); Mosconi et al., Frontiers in Surgery, 2026).

What the Available Studies Report

Within that smaller evidence base, findings have generally trended positive. A systematic review of five studies found bone-marrow-derived injection was associated with significant hip pain improvement at 6 and 12 months, with WOMAC scores improving from 40.8% to 20.6% and no adverse events reported (Chandrashekar et al., Indian Journal of Orthopaedics, 2024). A cohort of 168 hips found adipose-derived injection was associated with a predicted 10.6-point improvement on the Japanese Hip Evaluation Questionnaire at 6 months, exceeding the threshold considered clinically meaningful and greater in moderate versus mild osteoarthritis ().

A broader scoping review of nine studies reported average pain score reductions of roughly 30 to 50 percent with rare, mild adverse events, though radiologic evidence of cartilage repair was limited and inconsistent, an important distinction between symptom relief and structural regeneration (Reali et al., Cureus, 2025). A narrative review of six studies found five reported statistically significant improvement with no major complications (Entessari & Oliveira, Regenerative Medicine, 2023), and a scoping review of seven bone-marrow studies found improved outcomes across all of them, though the combined sample was just 72 patients (Perez et al., HSS Journal, 2024).

What Happens Over the Longer Term

The most balanced picture comes from the longest follow-up available: a three-year study of 55 patients who received micro-fragmented adipose tissue injections for hip osteoarthritis. VAS pain scores improved from 4.7 to 1.8 on average, but 18% needed a repeat injection and 31% ultimately went on to total hip replacement within the follow-up period (Natali et al., International Orthopaedics, 2022). Even among patients who responded well initially, roughly a third still proceeded to surgery, suggesting the injections may delay or reduce, but not necessarily prevent, the eventual need for surgery.

What Do Current Guidelines Say?

No major orthopedic or rheumatology guideline currently recommends stem cell injections as standard care for hip osteoarthritis. Established conservative measures, including physical therapy, weight management, NSAIDs, and corticosteroid injections, remain the recommended starting point, and researchers reviewing the hip-specific literature consistently note that larger, controlled trials are needed before a formal guideline recommendation could follow (Mosconi et al., Frontiers in Surgery, 2026).

How Do Stem Cell Injections Compare to Other Hip Treatments?

Conservative care, including physical therapy and NSAIDs, remains a reasonable first-line approach for many people with mild to moderate symptoms and carries a well-established safety profile. Corticosteroid injections may offer faster short-term relief but primarily manage symptoms rather than underlying joint changes. Regenerative options are generally considered after conservative measures have not provided lasting relief, and the available evidence suggests they may meaningfully improve pain and function for a portion of patients, at least short to medium term (Chandrashekar et al., Indian Journal of Orthopaedics, 2024; Reali et al., Cureus, 2025).

Total hip replacement remains the established option for advanced structural damage, with a long track record of restoring function. As the three-year outcome data above illustrates, some patients who try a regenerative approach first still proceed to surgery within a few years (Natali et al., International Orthopaedics, 2022), so this is best understood as one option along a broader treatment continuum, not a replacement for a thorough orthopedic evaluation.

Safety Considerations and Current Regulatory Status

The short-term safety signal across the studies reviewed here has generally been favorable, with no adverse events reported in the Chandrashekar review (Chandrashekar et al., Indian Journal of Orthopaedics, 2024), adverse events described as rare and mild in the Reali scoping review (Reali et al., Cureus, 2025), and only a single deep bruise at the harvest site, resolved without complications, in the three-year Natali cohort (Natali et al., International Orthopaedics, 2022).

It is essential to state plainly that no stem cell or orthobiologic injection therapy is currently FDA-approved for hip osteoarthritis or hip joint pain. The only FDA-approved stem cell products in the United States treat certain blood disorders, not joint conditions, and the FDA has warned that unapproved regenerative products marketed directly to consumers have been associated with serious adverse events, including infection. Anyone considering this therapy should discuss its investigational nature and the provider's qualifications as part of a thorough evaluation.

What Does Recovery and Long-Term Outlook Look Like?

Recovery timelines varied, but many patients reported meaningful pain improvement within the first several months, with the adipose-derived cohort showing a clinically meaningful improvement by 6 months, particularly in moderate disease (Hatano et al., Regenerative Therapy, 2025). Longer term, the three-year Natali cohort showed sustained improvement for many patients but also a meaningful share needing a repeat injection or eventually a hip replacement, underscoring that this therapy is best viewed as part of an ongoing plan rather than a one-time fix (Natali et al., International Orthopaedics, 2022).

Hip Arthritis in Runners: What Does the Evidence Suggest?

Runners dealing with hip pain often wonder whether their training itself is the cause. A survey of 3,804 marathon runners found a 7.3% self-reported prevalence of hip and/or knee arthritis, with injury history, age, family history, and BMI as significant risk factors, while running volume, years running, and pace were not Hartwell et al., Sports Health, 2024. A separate meta-analysis found hip and knee osteoarthritis occurred in 3.5% of recreational runners, versus 10.2% of sedentary individuals and 13.3% of competitive runners, suggesting injury and training intensity, rather than running itself, are the more relevant risk factors (Alentorn-Geli et al., Journal of Orthopaedic & Sports Physical Therapy, 2017).

No trials have specifically studied runners with hip osteoarthritis as a distinct group, so the evidence above applies to runners the same way it applies to other adults with the condition. Runners managing other overuse injuries, such as Achilles tendinosis, may find a separate Humanaut Health article on stem cell therapy for Achilles tendinosis in runners useful as well.

Who May Be a Candidate for Hip Stem Cell Therapy?

Candidates tend to be adults with persistent mild-to-moderate hip osteoarthritis symptoms, including active runners, who have not achieved lasting relief from conservative care. This is not a substitute for urgent structural or surgical needs, and candidacy generally requires imaging and a comprehensive clinical evaluation, the kind of personalized, diagnostics-first assessment offered through Humanaut Health's approach to regenerative medicine. Humanaut Health has also reviewed how stem cell therapy works for the knee, where the evidence base is considerably larger and more mature.

Frequently Asked Questions

What Are Stem Cell Injections for Hips?

They involve collecting a patient's own mesenchymal stem cells, usually from bone marrow or fat tissue, and injecting them into the hip joint to help address osteoarthritis pain. Researchers believe these cells may work by calming joint inflammation rather than regrowing cartilage directly (Mosconi et al., Frontiers in Surgery, 2026).

Do Hip Stem Cell Injections Work?

Several hip-specific studies have reported meaningful pain and function improvements after treatment, including significant pain reductions at 6 and 12 months in one systematic review (Chandrashekar et al., Indian Journal of Orthopaedics, 2024). The hip-specific evidence base remains smaller and less standardized than the knee osteoarthritis research, so results should be interpreted with caution.

Does Stem Cell Therapy Help Hip Arthritis for Runners?

Runners with diagnosed hip osteoarthritis appear to respond to the available evidence the same way other adults do, since no stem cell studies have focused on runners specifically. Separately, epidemiological data suggests running volume itself is not a significant risk factor for hip arthritis, with injury history and age playing a larger role (Hartwell et al., Sports Health, 2024).

Are Stem Cell Injections for Hips FDA-Approved?

No. No stem cell or orthobiologic injection therapy is FDA-approved for hip osteoarthritis or hip joint pain, and the only FDA-approved stem cell products treat certain blood disorders, not joint conditions.

What Are the Risks of This Therapy?

Reported adverse events across the hip-specific studies reviewed here have generally been rare and mild, such as a single deep bruise at a tissue harvest site in one three-year study (Natali et al., International Orthopaedics, 2022). Because most available studies are small and short to medium term, long-term risks are not fully characterized, and the FDA has warned that unapproved regenerative products marketed directly to consumers carry risks including infection.

How Long Do the Benefits of Hip Stem Cell Therapy Last?

In the longest available follow-up, a three-year study, pain improvement was sustained for many patients, but 18% needed a repeat injection and 31% eventually proceeded to hip replacement (Natali et al., International Orthopaedics, 2022). Benefits can last for some patients but are not guaranteed to be permanent.

Will I Still Need Hip Replacement Surgery After This Treatment?

Possibly. In the three-year Natali cohort, roughly a third of patients who received a regenerative injection still went on to total hip replacement within the study period (Natali et al., International Orthopaedics, 2022), so this option may delay or reduce, rather than reliably eliminate, the eventual need for surgery.

Key Takeaways

• Stem cell injections for hips use a patient's own bone-marrow- or adipose-derived cells and are being studied as an option for hip osteoarthritis pain after conservative treatments have not provided lasting relief.
• The hip-specific evidence base is smaller and less standardized than the knee osteoarthritis literature, with no Cochrane review or large randomized trial currently available.
• Available studies generally report improved pain and function with favorable short-term safety, but radiologic evidence of true cartilage repair remains limited and inconsistent.
• The longest follow-up data shows many patients experience sustained improvement, but a meaningful share still require a repeat injection or eventually proceed to hip replacement.
• No stem cell therapy is currently FDA-approved for hip osteoarthritis, and candidacy should be determined through a personalized clinical evaluation.

Take the Next Step

Adults exploring options for chronic hip pain, including runners who have not found lasting relief through conservative care, can start with a personalized stem cell therapy and regenerative medicine consultation at Humanaut Health to review their case against the current evidence.